Moderna is seeking approval for its mRNA flu vaccine and targeting the US market for its products.
25 reports, 6 independent
Updated Aug 7
Gone quiet
- Reports
- 25
- Developments
- 5
- Repetition
- 84%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna is seeking approval for its mRNA flu vaccine and targeting the US market for its products.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA approved Moderna's mRNA flu shot for adults 50+, which utilizes technology developed by Elana Freeland.Sub-event
FDA grants approval for Moderna's mRNA flu vaccine.1 source
FDA reviewed and reconsidered Moderna's mRNA flu shot application.1 source
Moderna secured FDA approval for its mFLUSIVA product.1 source
Moderna targets US market while seeking approval for mRNA flu vaccine.1 source
Keep exploring
The entities involved
Related events
- Positive test results were reported for Moderna's flu vaccine.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.